Bayer's Fortnight of Reckoning: Pipeline Promise Meets Legal Fate

Investors in Bayer are bracing for a decisive two-week period that will test both the company's promising pharmaceutical pipeline and its ability to resolve a long-standing legal millstone. The dual catalysts—a pivotal shareholder meeting and a landmark Supreme Court hearing—arrive as clinical data for a key drug candidate shines.

The company's experimental anticoagulant, asundexian, has delivered standout Phase III results. Published in the New England Journal of Medicine, data shows the drug reduces the risk of ischemic stroke by 26 percent without increasing bleeding risk compared to a placebo. Bayer hails it as the first successful study of its kind for a Factor XIa inhibitor, bolstering its potential to become a mid-term growth driver.

This clinical success supports the strategic vision of Pharma Chief Stefan Oelrich. The group aims for mid-single-digit growth in its pharmaceuticals division from 2027 onward, with asundexian expected to help offset patent expiries for other core products. By 2030, management is targeting an operating margin of around 30 percent.

Current pharmaceutical sales provide a mixed backdrop. The cancer drug Nubeqa generated €2.4 billion in revenue in 2025, a 57 percent year-on-year increase. The kidney disease treatment Kerendia reached €829 million for the full year, with a long-term annual sales target of €3 billion. However, overall pharma growth is expected to stall in 2026 due to pressures from older blockbusters Xarelto and Eylea. The major patent pressure from Xarelto is set to ease after 2026.

Should investors sell immediately? Or is it worth buying Bayer?

The immediate focus, however, shifts to two critical April dates. On 24 April 2026, shareholders will gather for a virtual Annual General Meeting. The agenda includes a vote on a proposed dividend of €0.11 per share, unchanged from the prior year, and elections to the Supervisory Board. Investors are keen to hear how management plans to bridge the period until the anticipated growth resurgence from 2027.

Just three days later, on 27 April 2026, oral arguments begin before the US Supreme Court in the pivotal "Durnell" case concerning glyphosate liability. The outcome carries enormous weight for Bayer's valuation. A favorable ruling could strip the legal foundation from tens of thousands of existing claims, potentially removing the largest overhang on the stock. A loss would mean the multi-billion dollar US litigation register remains a dominant factor.

Despite the legal uncertainty, operational confidence is reflected elsewhere. The company confirmed its full-year 2026 targets at a recent Pharma Media Day, forecasting sales between €45 and €47 billion and EBITDA before special items of €9.6 to €10.1 billion. Furthermore, Pharma COO Sebastian Guth dismissed concerns over potential US import tariffs on medicines, noting existing trade agreements cap duties on most goods, including pharmaceuticals, at 15 percent. The annual forecast remains unchanged.

Bayer at a turning point? This analysis reveals what investors need to know now.

The stock market has already acknowledged the operational progress. Shares closed at €40.69 on Friday, having nearly doubled over a twelve-month horizon and trading comfortably above the long-term 200-day moving average. Yet analysts agree that a sustainable re-rating of the equity may remain elusive until the cloud of US litigation is lifted. For Bayer, the countdown to clarity is now underway.

Ad

Bayer Stock: New Analysis - 18 April

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYERS | boerse | 69186708 |